BidaskClub upgraded shares of NxStage Medical (NASDAQ:NXTM) from a hold rating to a buy rating in a research note published on Thursday, May 31st.

A number of other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of NxStage Medical from a hold rating to a strong sell rating in a research report on Tuesday, May 15th. ValuEngine upgraded shares of NxStage Medical from a sell rating to a hold rating in a research report on Monday, April 2nd. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company’s stock. NxStage Medical has a consensus rating of Hold and an average target price of $30.71.

NxStage Medical traded up $0.32, reaching $28.48, during trading hours on Thursday, Marketbeat reports. The company’s stock had a trading volume of 812,400 shares, compared to its average volume of 520,691. The stock has a market cap of $1.86 billion, a PE ratio of -129.18 and a beta of -0.07. NxStage Medical has a 1 year low of $22.68 and a 1 year high of $29.93.

NxStage Medical (NASDAQ:NXTM) last issued its earnings results on Thursday, May 10th. The medical device company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). The business had revenue of $107.30 million during the quarter, compared to analysts’ expectations of $106.95 million. NxStage Medical had a negative return on equity of 6.98% and a negative net margin of 3.64%. equities research analysts predict that NxStage Medical will post -0.01 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in NXTM. Schwab Charles Investment Management Inc. increased its position in shares of NxStage Medical by 4.4% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 307,037 shares of the medical device company’s stock valued at $7,440,000 after acquiring an additional 12,894 shares during the period. Gabelli Funds LLC increased its position in shares of NxStage Medical by 24.8% in the fourth quarter. Gabelli Funds LLC now owns 223,324 shares of the medical device company’s stock valued at $5,411,000 after acquiring an additional 44,311 shares during the period. GABELLI & Co INVESTMENT ADVISERS INC. increased its position in shares of NxStage Medical by 31.3% in the fourth quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 336,590 shares of the medical device company’s stock valued at $8,156,000 after acquiring an additional 80,308 shares during the period. Gamco Investors INC. ET AL increased its position in shares of NxStage Medical by 10.2% in the fourth quarter. Gamco Investors INC. ET AL now owns 24,403 shares of the medical device company’s stock valued at $591,000 after acquiring an additional 2,250 shares during the period. Finally, Public Employees Retirement Association of Colorado purchased a new position in shares of NxStage Medical in the fourth quarter valued at about $128,000. Hedge funds and other institutional investors own 82.10% of the company’s stock.

About NxStage Medical

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Analyst Recommendations for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.